Benzinga | May 5, 2021 04:27PM EDT

Allogene Therapeutics Q1 EPS $(0.25) Beats $(0.46) Estimate, Sales $38.34M Beat $13.92M Estimate; Sees FY21 GAAP Opex $300M-$330M

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.46) by 45.65 percent. This is a 50 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $38.34 million which beat the analyst consensus estimate of $13.92 million by 175.47 percent.